GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Farmaceutica Remedia SA (BSE:RMAH) » Definitions » 3-Year EPS without NRI Growth Rate

Farmaceutica Remedia (BSE:RMAH) 3-Year EPS without NRI Growth Rate : 32.10% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Farmaceutica Remedia 3-Year EPS without NRI Growth Rate?

Farmaceutica Remedia's EPS without NRI for the three months ended in Dec. 2023 was lei0.01.

During the past 12 months, Farmaceutica Remedia's average EPS without NRI Growth Rate was 24.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 32.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Farmaceutica Remedia was 81.70% per year. The lowest was -29.80% per year. And the median was 4.40% per year.


Competitive Comparison of Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate

For the Medical Distribution subindustry, Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate falls into.



Farmaceutica Remedia 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Farmaceutica Remedia  (BSE:RMAH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Farmaceutica Remedia 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Farmaceutica Remedia's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Farmaceutica Remedia (BSE:RMAH) Business Description

Traded in Other Exchanges
N/A
Address
No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.

Farmaceutica Remedia (BSE:RMAH) Headlines

No Headlines